Grade My Investments
HomeFree Stock Grades › ZVRA

Zevra Therapeutics, Inc. (ZVRA) Stock Grade

ZVRA · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$495.6M
P/E Ratio
6.0
Revenue Growth (YoY)
+350.9%
Net Margin
78.2%
Return on Equity
53.8%
Dividend Yield
None

About Zevra Therapeutics, Inc.'s fundamentals

Zevra Therapeutics is a biotechnology company with a market capitalization of $495.6 million that is experiencing exceptional growth, with revenue surging 350.9% year-over-year. The company maintains a remarkably high net margin of 78.2% and achieved a return on equity of 53.8%, indicating strong profitability and efficient use of shareholder capital. Trading at a P/E ratio of 6.0 suggests the stock is valued relatively modestly compared to its earnings, though the company does not currently pay a dividend.

Track ZVRA free — no credit card required. Live grade + monthly AI report →